Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–68 of 68 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: SSc Clear all
Terminated Phase 2 Interventional Results available

Abituzumab in SSc-ILD

NCT02745145
View directory record Official record
Conditions
Systemic Sclerosis-associated Interstitial Lung Disease
Interventions
Abituzumab 1500 mg, Abituzumab 500 mg, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
18
States / cities
Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 23, 2026, 4:22 AM EDT
Recruiting Not applicable Interventional

A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Cancer

NCT07218250
View directory record Official record
Conditions
Breast Cancer
Interventions
Single Counseling Session, American Cancer Society booklet
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Terminated No phase listed Observational

Evaluation of the Patient Safety Screening Tool (PSST) for Sepsis

NCT00698542
View directory record Official record
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 23, 2026, 4:22 AM EDT
Recruiting Phase 1 Interventional

US Zamto-cel Autoimmune Diseases

NCT06708845
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
Interventions
zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Miltenyi Biomedicine GmbH
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Recruiting Phase 2 Interventional

Intralesional Injection of STS in Treatment of Calcinosis

NCT06672822
View directory record Official record
Conditions
Systemic Sclerosis (SSc), Dermatomyositis, Mixed Connective Tissue Disease (MCTD), Calcinosis
Interventions
Sodium Thiosulfate (STS)
Drug
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Recruiting Phase 1 Interventional

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

NCT07115745
View directory record Official record
Conditions
Refractory Autoimmune Diseases
Interventions
BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab
Genetic · Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

NCT02780674
View directory record Official record
Conditions
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
Interventions
MEDI7734, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Anniston, Alabama • Birmingham, Alabama • Danbury, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Not applicable Interventional

Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma

NCT02837549
View directory record Official record
Conditions
Scleroderma, Ssc
Interventions
Occupational therapy treatment
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 23, 2026, 4:22 AM EDT
Not yet recruiting Phase 1 Interventional

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease

NCT07729995
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
Interventions
LMY-922
Biological
Lead sponsor
Luminary Therapeutics
Industry
Eligibility
16 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

Taking Charge of Systemic Sclerosis

NCT02494401
View directory record Official record
Conditions
Scleroderma
Interventions
Internet-based self-management program, Scleroderma book
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 4:22 AM EDT
Terminated Phase 1 Interventional

Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

NCT00418132
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Thalidomide, Placebo thalidomide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

TENS in Scleroderma

NCT06646913
View directory record Official record
Conditions
Scleroderma, Gastroparesis, Systemic Sclerosis (SSc)
Interventions
Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Recruiting Phase 2 Interventional

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

NCT04797286
View directory record Official record
Conditions
Scleroderma, Mildly Elevated Pulmonary Pressures
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet

NCT01072669
View directory record Official record
Conditions
Ischemia
Interventions
ambrisentan
Drug
Lead sponsor
Soumya Chatterjee
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

NCT03313180
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 23, 2026, 4:22 AM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

NCT05626751
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
Interventions
HZN-825
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment

NCT02530996
View directory record Official record
Conditions
Rheumatologic Disease
Interventions
BH4, Vasculopathy assessment, Placebo
Drug · Diagnostic Test
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 95 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

NCT02597933
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Nintedanib, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 23, 2026, 4:22 AM EDT
Enrolling by invitation Phase 1 Interventional

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

NCT06375993
View directory record Official record
Conditions
Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome
Interventions
ADI-001, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Adicet Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Redwood City, California • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Not listed Not applicable Interventional

The Small Intestine Bacterial Overgrowth Study Pilot

NCT03588845
View directory record Official record
Conditions
Systemic Sclerosis, Small Intestinal Bacterial Overgrowth
Interventions
Treatment Protocol, Standard of Care
Other
Lead sponsor
Canadian Scleroderma Research Group
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 23, 2026, 4:22 AM EDT